Benzinga | May 12, 2021 06:17AM EDT

SVB Leerink Maintains Outperform on Biohaven Pharma Hldgs, Lowers Price Target to $105

SVB Leerink analyst Marc Goodman maintains Biohaven Pharma Hldgs (NYSE:BHVN) with a Outperform and lowers the price target from $115 to $105.